[12] Patent
[11] Patent No.:GC0007673  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/126634
Date of the Decision to Grant the Patent:30/Apr/2018

[21] Application No.:GC 2014-26719

[22] Filing Date:13/3/2014

[30] Priority:

[33] State [32] Priority date [31] Priority No.
EP
EP
15/3/2013
18/11/2013
13275070.4
13193372.3

[72] Inventors:1- COPMANS, Alex, Herman،2- SMITH, Alun, John،3- BROECKX, Rudy, Laurent, Maria،4- TADDEI, David, Michel, Adrien،5- ONIONS, Stuart, Thomas

[73] Owner: Respivert Limited, 50 - 100 Holmers Farm Way, High Wycombe, HP 12 4EG, Buckinghamshire, United Kingdom

[74] Agent: Saba & Co. T.M.P

  

 

  

[51]IPC:
Int. Cl.: A61K 31/519; A61P 11/06; C07D 487/04 (2006.01)

[56] Cited Documents:

-WO 2011/048111 Al (RESPIVERT LTD [GB] ; KING-UNDERWOOD JOHN [GB] ; ITO KAZUHIRO [GB] ; MURRA) 28 April 2011  
Examiner: PH. Sarah A. AlGrainies

[54] COMPOUND
[57] Abstract: The present invention relates inter alia to a compound of formula (I) and to compositions comprising the same and to the use of the compounds and to compositions of the compounds in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making the said compounds.
No. of claims: 16     No. of figures: 17


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.